Utah Medical Products, Inc. (UTMD)

Utah Medical Products, Inc. experienced declines in Q2, Q3, and Q4 2025 earnings year-over-year, with a 6.3% drop in Q4 2025 EPS and a 5.8% decrease in full-year 2025 net sales to $38.5 million. Full-year 2025 net income decreased by 18.7% to $11.3 million, and EPS was down 12.1% to $3.483. Despite these challenges, the stock gained 2% since the Q4 and full-year 2025 earnings report, and shares climbed 7.6% over the past month. The company declared a dividend in July 2025, and the stock's 52-week range has been between $51.26 and $64.46. In early February 2026, the stock price moved below its 15-day moving average.

Specific information detailing the demand seasonality for Utah Medical Products, Inc.'s products and services is not readily available. The available data primarily discusses the seasonality of UTMD's stock returns, indicating that November has historically shown the highest probability of positive returns, while February has the lowest.

Utah Medical Products, Inc. specializes in proprietary, disposable, hospital-use medical devices within the healthcare sector, focusing on development, manufacturing, and distribution. Its product categories include blood pressure monitoring, blood collection, electrosurgery, gynecology, neonatal critical care, perinatology, and urology. Key products include electrosurgical pens, tenacula, and infusion therapy products, as well as labor and delivery products like fetal monitoring accessories and postpartum care devices.

UTMD has a global presence, selling directly to end-users in countries like Australia, New Zealand, Canada, France, Ireland, and the United Kingdom. It also works with over 300 international distributors in major developed and many underdeveloped countries. In 2022, international customers accounted for 39% of total sales, and 30% of employees were based outside the United States.

Utah Medical Products has maintained brand awareness among clinical users for its primary revenue contributors. However, the company's reputation has been impacted by ongoing litigation related to the Filshie Clip System, with increased litigation costs in Q4 2025. Fourteen of nineteen pending court cases had been dismissed by the end of January 2026. The company has also faced challenges from misinformation surrounding product safety related to PendoTECH and Filshie Clip issues.

Utah Medical Products, Inc. has 261 institutional owners and shareholders holding a total of 2,622,382 shares. Major institutional shareholders include Brandes Investment Partners, Lp, Renaissance Technologies Llc, and Dimensional Fund Advisors Lp. The CEO, Kevin Cornwell, holds a 5% stake in the company.